Back to Journals » Lung Cancer: Targets and Therapy » Volume 17 » default

PubMed
ESCI
SJR OA
CiteScore
Impact Factor

Lung Cancer: Targets and Therapy

COPE logo
ISSN: 1179-2728

Archive: Volume 17, 2026

Original Research

Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer

Liu SYM, Xie Z, Yan L, Jie GL, Deng JY, Zhang Q, Huang Z, Wang J, Zhang Z, Shao Y, Meng H, Zhang Y, Zhang XC, Chen HJ, Zhong WZ, Zhou Q, Wu YL

Lung Cancer: Targets and Therapy 2026, 17:596080

Published Date: 8 May 2026

Original Research

Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients

Lumjiaktase P, Kemawichanurat N, Santiwiwas K, Kuttiyod T, Oranratnachai S, Trachu N, Monnamo N, Khiewngam K, Simmalee K, Reungwetwattana T

Lung Cancer: Targets and Therapy 2026, 17:578622

Published Date: 16 March 2026

Original Research

Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China

Zhou J, Wang Y, Peng J, Tang KJ, Wu J, Chen Y, Xue Z, Wu YL

Lung Cancer: Targets and Therapy 2026, 17:555262

Published Date: 18 February 2026

Original Research

Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer

Schraps N, Reck M, Hantzsch-Kuhn B, Olchers T, Ellebrecht DB, Möller K, Fraune C, Lennartz M, Lutz F, Kluth M, Makrypidi-Fraune G, Simon R, Sauter G, Steurer S, Von Weihe S

Lung Cancer: Targets and Therapy 2026, 17:530791

Published Date: 6 January 2026